Patients: 66 women with social phobia (DSM-IV). Exclusions: ,18 years old; psychosis; severe major depressive episode; pregnancy; not using contraception; psychotherapy; suicidal; abusing drugs or alcohol; other illness; or current use of mirtazapine or other psychotropics.
Intervention: Mirtazapine (30 mg/day); placebo. 
MAIN RESULTS
At 10 weeks, mirtazapine improved symptoms of social anxiety compared with placebo in women with social phobia (difference in score change between mirtazapine and placebo: SPIN 8.1, 95% CI 29.6 to 4.1; p,0.001; LSAS 220.2, 95% CI 227.5 to 24.1; p,0.001 ). Mirtazapine also improved general health perceptions, vitality, social functioning, and mental health, and reduced role limitations due to emotional problems (p,0.001 for all; see http://www.ebmentalhealth.com/supplemental for table). There was no significant difference between mirtazapine and placebo in the physical aspects of quality of life (p.0.05; see http://www.ebmentalhealth.com/ supplemental for table). 
CONCLUSIONS

Commentary
S everal medications have shown efficacy for the treatment of social phobia. So far, the selective serotonin reuptake inhibitors (SSRIs) are recommended as first line treatment considering the evidence for safety and tolerability, ability to treat comorbid conditions, and stability of the effect size estimate shown across studies.
1 2 The efficacy and safety of mirtazapine, with a mode of action different from currently available antidepressants, has been established in people with depressive disorder.
3 4 Positive results from pilot studies of mirtazapine for the treatment of anxiety disorders have indicated potential for this medication. Muehlbacher et al present the first randomised, placebo controlled study of mirtazapine in people with social phobia. Mirtazapine shows rapid and credible effects and is relatively well tolerated. It lacks the side effects common with the SSRIs, such as sexual and sleep disturbances and nausea, which may affect patients' motivation to complete treatment. The overall response rate and the change score of the Liebowitz Social Anxiety Scale appears comparable to the reduction found with paroxetine and fluvoxamine.
1 Their findings suggest that mirtazapine could be an additional medication option for social phobia.
The effect of mirtazapine in this study is, however, representative of short term gains in young female non-psychiatric patients. Whether mirtazapine could be a credible option in clinical practice depends on if the results could be replicated in psychiatric samples that usually present with higher rates of comorbid symptoms and personality disorders, and in samples including both men and women with a wider age range. Moreover, it is important to evaluate the long term effects of the medication, which would provide further knowledge of the influence of side effects (such as sedation and weight gain) on treatment compliance. Ewa Mörtberg, PhD Karolinska Institute, Department of Clinical Neuroscience, Section of Psychiatry, St Göran, Stockholm, Sweden
